Resumen de Latest progress in molecular biology and treatment in genitourinary tumours

Aránzazu González del Alba Baamonde, J. A. Arranz Arija, Joaquim Bellmunt, Pablo Maroto Rey, Ovidio Fernández Calvo, B. Pérez Valderrama, Enrique González Billalabeitia, María José Méndez Vidal, Javier Cassinello Espinosa, Nuria Romero Laorden, Miguel Ángel Climent Durán, Javier Puente Vázquez, Ignacio Peláez Fernández, Martin Lázaro Quintela, Enrique Gallardo-Díaz, Cristina Suárez

• The management of genitourinary cancer, including bladder, prostate, renal and testicular cancer, has evolved dramatically in recent years due to a better understanding of tumour genetic mutations, alterations in molecular pathways, and to the development of new kinds of drugs such as targeted therapies and immunotherapies. In the field of immunotherapy, new drugs focused on stimulating, enhancing and modulating the immune system to detect and destroy cancer, have been recently discovered. Research in oncology moves quickly and new data of great relevance for clinical practice are communicated every year. For this reason, a group of experts, focused exclusively on the treatment of genitourinary tumours and who get together every year in the BestGU conference to assess the latest progress in this field have summarized the most important advances in a single review, along with a critical assessment of whether these results should alter daily clinical practice.